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Abstract
Background: Since the liver metastases rather than the colorectal cancer itself is the main determinant
of patient's survival, the ‘Liver-First Approach (LFA)’ with upfront chemotherapy followed by a hepatic
resection of colorectal liver metastases (CLM) and finally a colorectal cancer resection was proposed. The
aim of this review was to analyse the evidence for LFA in patients with colorectal cancer and synchronous
CLM.
Methods: A literature search of databases (MEDLINE and EMBASE) to identify published studies of LFA
in patients with colorectal cancer and synchronous CLM was undertaken focussing on the peri-operative
regimens of LFA and survival outcomes.
Results: Three observational studies and one retrospective cohort study were included for review. A
total of 121 patients with colorectal cancer and synchronous CLM were selected for LFA. Pre-operative
chemotherapy was used in 99% of patients. One hundred and twelve of the initial 121 patients (93%)
underwent a hepatic resection of CLM. In total, 60% had a major liver resection and the R0 resection rate
was 93%. Post-operative morbidity and mortality after the hepatic resection were 20% and 1%, respec-
tively. Ultimately, 89 of the initial 121 (74%) patients underwent a colorectal cancer resection. Post-
operative morbidity and mortality after a colorectal resection were 50% and 6%, respectively. The median
overall survival was 40 months (range 19–50) with a recurrence rate of 52%.
Conclusions: Current evidence suggests that LFA is safe and feasible in selected patients with color-
ectal cancer and synchronous CLM. Future studies are required to further define patient selection criteria
for LFA and the exact role of LFA in the management of synchronous CLM.
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Introduction
Colorectal cancer is the third most common cancer worldwide.1 Up
to 25% of patients have synchronous colorectal liver metastases
(CLM) at presentation2,3 and such synchronous presentation has
been associated with poor survival outcomes.4–6 Nevertheless, sur-
gical resection of all tumour sites is considered the only curative
therapy enabling long-term survival.4–6 The traditional surgical
strategy for patients with resectable synchronous CLM is a two-
stage approach that includes colorectal cancer resection followed
by chemotherapy and delayed hepatic resection of the CLM. One
disadvantage of this approach includes disease progression of CLM
between the colorectal and hepatic surgery rendering the CLM
unresectable.7 This is of particular concern in patients who develop
post-operative complications after colorectal cancer resection, pre-
cluding the administration of chemotherapy and hepatic resection
of CLM.8 In the last decade, simultaneous resection of colorectal
cancer and CLM has been increasingly used in selected patients
with comparable peri-operative morbidity and mortality as well as
survival outcomes.9,10 This approach however is associated with
increased post-operative complications when a major hepatic
resection of CLM is performed.9 The benefit of peri-operative
chemotherapy in patients undergoing a hepatic resection of
CLM has been increasingly apparent. Indeed a recent multicentre
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randomized controlled trial of 5-fluorouracil (5-FU) mono-
therapy demonstrated an increased disease-free survival and a
trend towards increased overall survival compared with a hepatic
resection of CLM alone.11 With the introduction of several effective
systematic cytotoxic and targeted agents, recent studies have also
demonstrated an improved response rate and survival outcomes in
patients with metastatic colorectal cancer.12 In patients with syn-
chronous CLM, the optimal sequence of colorectal cancer resec-
tion, hepatic resection of CLM and systematic chemotherapy has
not been clearly defined and remains controversial. Since the pro-
posal that liver metastases rather than the colorectal primary may
be the most common cause of a patient’s death, Mentha et al. 7
described the ‘Liver-First Approach (LFA)’ with chemotherapy
given upfront followed by hepatic resection of CLM and finally
colorectal cancer resection. This systematic review has been under-
taken to assess the published evidence for the safety and feasibility
of LFA in patients with synchronous CLM.
Methods
Literature search strategy
A search was undertaken of MEDLINE (1966 to July 2012) and
EMBASE (January 1974 to July 2012) databases. The search terms
colorectal cancer or colorectal neoplasm; liver metastases or hepatic
metastases; hepatectomy or liver resection or hepatic resection; liver-
first or reverse approach were used. These terms were mapped to
MEDLINE Subject Headings (MESH) terms as well as being
searched for as text items. Reference lists from relevant articles
were searched for other potentially relevant studies.
Study selection
The study evaluation was performed by two reviewers (V.L. and
J.L.). After the initial search, reviews, case reports, conference
abstract, non-human studies or case series including less than 10
patients completing the LFA were excluded. Abstracts of the
remaining studies were retrieved and then reviewed for relevance.
The full text of the selected articles was thoroughly reviewed.
Studies from which a decision could not be made based upon the
abstract were also reviewed. Those studies which described the use
of the LFA with curative intent in patients with colorectal cancer
and synchronous CLM were included for analysis. Studies that
adopted a hybrid approach combining liver resection with abla-
tion techniques, or two-stage hepatectomy, or resection of extra-
hepatic metastases with the aim of expanding the criteria for
resection of CLM, were also included for review. Only studies
reporting both short- and long-term outcomes of LFA were
included. When multiple publications were identified from the
same or overlapping patient series, only the most complete or
recent publication was included. Study methodology quality was
assessed according to the Newcastle–Ottawa scale.13 A score of
four or more was required for inclusion.
Data extraction and critical appraisal
Two reviewers (V.L and J.L.) independently appraised each article
using predefined criteria. Data extracted included the methodol-
ogy, quality criteria, the setting of the use of peri-operative
chemotherapy, the response to chemotherapy, the proportion of
R0 resections, the overall survival (OS); the morbidity and mor-
tality of this multimodality approach. Discrepancies were resolved
by consensus. A major hepatectomy was defined as a resection of
three or more Couinaud segments. Owing to the lack of a control
group and the heterogeneity present amongst the selected studies,
a meta-analysis could not be carried out. According to PRISMA
guidelines,14 a systematic review was performed without a com-
parator group by full tabulation of the results. The level of evi-
dence of each article was scored according to the Hierarchy of
Evidence table.15
Results
The literature search using the above-described strategy identified
697 studies. Duplicated studies, non-human studies, review arti-
cles, case report and conference abstract were excluded. The
manuscripts of the 13 remaining articles were reviewed. Nine
articles not fulfilling the inclusion criteria were excluded. The
remaining 4 studies were individually reviewed (Fig. 1). No meta-
analyses or randomized control trials were identified.
This review comprised of 3 observational studies (level IV evi-
dence) and 1 retrospective cohort (level III evidence) study.
Overall, 121 patients with synchronous colorectal cancer and
CLM were selected for the LFA.16–19 Two studies with overlapping
patient series7,20 were excluded as well as a case report.21 Selection
criteria for the LFA were reported in 4 studies and none of these
studies used the same criteria (Table 1).16–19 One study considered
all patients with primary rectal cancer with synchronous CLM19
whereas another study included only patients with locally
advanced rectal cancer with synchronous CLM.17 Three of the
four studies included patients with both colon or rectal can-
cer16,18,19 while one study included rectal cancer only.17 Three
studies reported the proportion of rectal and colon cancer
primary sites (Table 2) with a total of 70/86 (81%, range
68–100%) patients having primary rectal cancer. Three studies
reported the proportion of patients with colonic symptoms, and a
total of 39/40 (98%) were symptomatic at the time of presenta-
tion.16,17,19 Two studies defined the criteria of resectability of
CLM16,19 according to a previous consensus conference of the
surgical management of CLM.22 All four studies used modern
pre-operative chemotherapy (Oxaliplatin or Irinotecan-based
regimens  bevacizumab and/or cetuximab) with a total of 99%
(120/121) of patients treated.16–19 However, the dosage and dura-
tion of the pre-operative chemotherapy regimens were not
uniform. One study also included pelvic radiation in the pre-
operative chemotherapy phase before hepatic resection of CLM.19
The rate of response of CLM to pre-operative chemotherapy was
reported in only one study with a complete response rate of 1/22,
a partial response rate of 15/22 and a stable response rate of 6/22.17
All four studies reported colonic complications during pre-
operative chemotherapy but only 6/120 (5%) (range, 3–10%)
102 HPB
HPB 2014, 16, 101–108 © 2013 International Hepato-Pancreato-Biliary Association
patients required an emergency colorectal cancer resection with
no mortality.16–19 Overall, one patient died of fungal sepsis during
the pre-operative chemotherapy phase.16
The surgical characteristics and peri-operative outcomes of the
first stage (hepatic resection of CLM) of LFA are depicted in
Table 3. Two studies reported the proportion of concomitant
colorectal resection with a value of 7/31 and 1/22, respectively, in
each study.16,17 A liver resection was performed in all four studies
with a total of 112/121 (93%, range 83–100%) patients undergo-
ing a liver resection.16,17 The R0 resection rate and proportion of
major liver resections were reported in three studies with a total of
62/67 (93%, range 85–100%) and 40/67 (60%, range 32–89%)
patients, respectively.17–19 Post-operative morbidity was reported
in 3 studies with a total morbidity rate of 13/64 (20%) (range,
9–27%).17–19 Overall, there was one peri-operative mortality after
the first stage of LFA.19 Interval chemotherapy  pelvic radiation
was reported in three studies with a total of 39/68 (57%, range
18–100%) patients receiving such treatment.17–19 The interval
duration between the first and second stage of LFA was reported
in two studies with a median interval duration of 4 weeks and 3
months, respectively, in each study.17,19
Thirty of the initial 121 (25%) patients did not progress to the
second stage of LFA. Interval disease progression (26/30) was the
main reason followed by disappearing primary (2/30) and death
before the second stage of LFA (2/30). The surgical characteristics
and peri-operative outcomes of the second stage (colorectal
cancer resection) of the LFA are depicted in Table 4. Eighty-nine
of the initial 121 (74%) patients ultimately underwent a colorectal
cancer resection. Post-operative morbidity was reported in two
studies with a rate of 1/30 and 8/16, respectively.16,19 Post-
operative mortality was reported in 3 studies and there was one
[1/62(2%)] post-operative death.16,17,19
Overall, 91 of the initial 121 (75%) patients completed both
stages of the LFA including 89 patients who underwent a colorec-
tal cancer resection and 2 patients with disappearing rectal cancer
primary after peri-operative chemoradiation. The survival out-
comes after completion of LFA are depicted in Table 4. The
follow-up time was reported in two studies with a median
follow-up of 18 and 25 months, respectively.17,18 Survival out-
comes were reported in all four studies. The median OS of
patients who completed both stages of the LFA was reported in all
4 studies with values of 19, 36, 44 and 50 months, respectively.16–19
The recurrence rate was reported in all four studies with a total of
47/91 (52%) (range, 13–70%) patients suffering recurrence.16–19
Three-year OS post-completion of the LFA was reported in all 4
studies with values of 41%, 60%, 79% and 89% respectively16–19
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Figure 1 Flow chart showing the search strategy used to identify studies
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whereas 5-year OS post-completion of LFA was reported in 3
studies with the value of 31%, 39% and 89%, respectively.16–18
Discussion
This systematic review demonstrates that LFA in selected patients
with synchronous colorectal cancer and CLM is associated with
low peri-operative morbidity and mortality and acceptable sur-
vival outcomes. The 3-year OS ranged from 41% to 89% whereas
the 5-year OS was 31% to 89%. These outcomes are comparable
with those of a hepatic resection in selected patients with resect-
able CLM after the colorectal cancer resection.4–6 Although the
LFA has been discussed widely among hepatobiliary surgeons in
international and regional hepatobiliary surgery conferences,23,24
only four surgical series with a total of 91 patients who completed
the LFA were identified and thus the results should be interpreted
with caution.
Although the value of a hepatic resection for CLM has never
been demonstrated in a prospective randomized controlled trial,
numerous surgical series have demonstrated the possibility of
long-term survival. Additionally, no other treatment apart from a
liver resection has shown a survival plateau. Recently, a number of
case series describing 10-year actual survivors after a liver resec-
tion of CLM have also been published.5,6 These results support
liver resection as the standard practice as well as the only curative
treatment for CLM.
In this systematic review, there were no uniform patient selec-
tion criteria for the LFA and it is a significant limitation to the
critical evaluation of outcomes of this approach. The majority of
the selected patients who had rectal cancer [70/86 (81%) and
39/80 (49%)] had colonic symptoms at the time of presentation.
Two of the 4 studies made reference to the recent consensus con-
ference CLM resectability criteria as part of the patient selection
criteria. It was unclear whether the remaining two studies
included patients with definitely resectable, borderline resectable
or unresectable CLM or a combination of these three. Pre-
operative chemotherapy with oxaliplatin- or irinotecan-based
regimens with bevacizumab and/or cetuximab were administered
in 120/121 (99%) of patients and appeared to be an integral part
of the LFA. This was followed by a hepatic resection in 112/121
(93%) of patients and ultimately colorectal cancer resection in
89/121 (74%) of patients. Thirty out of 121 (25%) patients did not
complete all stages of the LFA with disease progression being the
most common reason.
The timing and sequence of therapeutic interventions in
patients presenting with synchronous CLM has not been clearly
defined and the decision whether to go ‘Bowel-First’, ‘Simultane-
ous’ or ‘Liver-First’ remains controversial.25 For patients present-
ing with severe symptoms related to the intact colorectal cancer,
the decision to resect the colorectal cancer first is straightfor-
ward.26 However, the intact colorectal cancer is asymptomatic in
the majority of patients. The traditional ‘Bowel First’ approach is
Table 1 Setting of the studies reporting the results of the liver-first approach (LFA) in patients with synchronous colorectal liver metastases
including the selection criteria of LFA
Reference Year of
publication
Country Setting Study period Selection criteria of ‘LFA’
Mentha16 2008 Switzerland Prospective
observational
study
1998–2007 • Advanced synchronous colorectal liver metastasesa
• Age <70
• Performance status <2
• Non-occlusive primary tumour
• At least two liver segments without metastases
• No or resectable extrahepatic disease
Clinical risk score >3
Verhoef17 2009 Netherlands Retrospective
observational
study
2003–2007 • Synchronous liver metastases
• Locally advanced rectal cancer and where it is defined as:
1 tumour>5 cm at colonoscopy or MRI (clinically large T3); or
2 clinically fixed tumor or with ingrowth in adjacent organ on
MRI (T4); or
3 N + tumor (lymph node>8 mm on CT or MRI)
Brouquet18 2010 United States Retrospective
cohort study
1992–2009 • Synchronous colorectal liver metastases
• Criteria not specifically stated but liver resection is planned
as soon as the disease was considered resectable, typically
after 3 to 5 cycles of preoperative chemotherapy
De Jong19 2011 Netherlands Retrospective
Observational
study
2005–2010 • Synchronous colorectal liver metastases
• Liver remnant post resection includes at least two adjacent
liver segments as well as sufficient vascular inflow and
outflow and adequate biliary drainage
• All patients with a primary rectal cancer were considered for
the liver-first approach
• Patients with colorectal cancer located in the colon were
selected on a case-to-case basis
aCriteria of ‘Advanced Synchronous Colorectal Liver metastases’ was not clearly defined.
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a two-stage procedure that includes colorectal cancer resection
followed by delayed hepatic resection of CLM. Arguments for an
initial colorectal cancer resection in these patients include: (i) if
the tumour obstructs, bleeds or perforates, emergency surgery is
required, which is associated with a higher peri-operative morbid-
ity and mortality; and27 (ii) the interval time period between a
colorectal resection and hepatic resection may allow occult sys-
tematic disease to become detectable.28 Patients with disease pro-
gression rendering the disease unresectable can thus be spared the
peri-operative morbidity and mortality of futile hepatic surgery.
Several arguments however have been posited against upfront
colorectal resection: (i) over the past decade, peri-operative
Table 2 Patient characteristics, systemic chemotherapy and response to treatment
Reference Total patients
selected initially
for ‘Liver-first
Approach’
Rectal
Primary
n (%)
Colonic
symptoms
at the time of
presentation
n (%)
Preoperative
chemotherapy
n (%)
Chemotherapy
regimens
Radiological
response
rate of
chemotherapya
n (%)
Colonic
complications
during
chemotherapy
n (%)
Mentha16 35 NR 0 (0) 35 (100) Oxalipatin, Irinotecan,
5-FU, leucovorin 
bevacizumab and/or
cetuximab
NR 1/35b (3)
Verhoef17 23 23 (100) 23 (100) 22 (96) 5-FU/Capecitabine,
Oxaliplatin or Irinotecan
 bevacizumab
16/22 (73) 1/22c (5)
Brouquet18 41 28 (68) NR 41 (100) 5-FU, Oxaliplatin or
Irinotecan 
bevacizumab and/or
cetuximab
NR 2/41d (5)
De Jong19 22 19 (86) 16 (73) 22 (100) • Non-locally advanced
rectal cancer:
Short course pelvic
radiation (5X5 Gy) + 3
cycles of oxaliplatin 
bevacizumab
• Locally advanced rectal
cancer(T3-4, N1-2):
Long course pelvic
radiation (28 fractions
of 1.8 Gy radication)
with capecitabine + 2
cycles of oxaliplatin 
bevacizumab
NR 2/22e (10)
Total percentage 70/86 (81) 39/80 (49) 120/121 (99) 6/120 (5)
Range 68–100 0–100% 3–10
Total 121
aComplete or partial response.
bColonic occlusion requiring an emergency Hartmann's procedure.
cCaecal perforation requiring an emergency colectomy.
dSymptomatic requiring an emergency colostomy.
Table 3 Surgical characteristics and peri-operative outcomes of a liver resection stage of the liver-first approach (LFA)
Reference Number of
patients underwent
liver resection
n (%)
Synchronous
liver and bowel
resections
n (%)
R0
resection
n (%)
Major
liver
resection
n (%)
Perioperative
Morbidity
n (%)
Perioperative
Mortality
n (%)
Interval
chemotherapy 
radiation
n (%)
Mentha16 31/35 (89) 7 (23) NR NR 5 (16) 0 NR
Verhoef17 19/23 (83) 1 (5) 19 (100) 6 (32) 2 (9) 0 19 (100)
Brouquet18 41/41 (100) NR 23/27a (85) 24/27a (89) NR 1/27a (4) 16/27a (59)
De Jong19 21/22 (95) NR 20 (95) 10 (48) 6 (27) 0 4 (18)
Total Percentage 112/121 (93) 62/67 (93) 40/67 (60) 13/64 (20) 1/91 (1) 39/68 (57)
aTwenty-seven of the initial 41 patients completed both liver and bowel resection; R0 and major liver resection rates and peri-operative outcomes were
reported in these 27 patients.
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chemotherapy followed by a hepatic resection is increasingly per-
formed in patients with resectable CLM. In a randomized con-
trolled study, 5-FU-based peri-operative chemotherapy followed
by a hepatic resection was associated with increased disease-free
survival and a trend towards increased overall survival when com-
pared with a hepatic resection alone.11 Furthermore, modern
chemotherapy regimens using a combination of 5-FU plus oxali-
platin and/or irinotecan has produced even better response rates
with a partial response rate up to 50% and a median survival
approaching 2 years in patients with unresectable metastatic
colorectal cancer.29,30 The addition of biological agents such as
bevacizumab and cetuximab has been shown to further improve
the response rate;31,32 (ii) in patients with intact colorectal cancer
and synchronous CLM, it has been shown that pre-operative
chemotherapy with oxaliplatin- and/or irinotecan-based regi-
mens induced a major histological response of 70% in colorectal
cancer. Such a response was also significantly correlated with a
response of the corresponding CLM; (iii) recent studies demon-
strated that colorectal cancer resection in patients with metastatic
colorectal cancer was associated with a significantly higher 30-day
mortality of 10% when compared with a colorectal cancer resec-
tion in the non-metastatic setting; 33,34 (iv) the potential colonic
complications of leaving the colorectal cancer intact may have
been overstated. The rate of surgical intervention for colonic com-
plications was only 20% in one review of 255 patients with meta-
static colorectal cancer treated primarily with 5-FU.27 Poultsides
et al. 27 published the Memorial Sloan-Kettering Cancer Centre
experience of 233 patients with metastatic colorectal cancer with
an intact primary tumour. The incidence of colonic complications
was 7% with the use of modern oxaliplatin- or irinotecan-based
chemotherapy. A recent multi-institutional NSABP Trial C-10
prospectively followed 86 patients with asymptomatic colon
cancer and unresectable metastases. All patients were treated with
infusional 5-FU, leucovorin and oxaliplatin (mFOLFOX6) com-
bined with bevacizumab. The incidence of a significant colonic
complication was 12/86 (14%) with 10 patients requiring surgery
(8 for an obstruction, 1 for perforation and 1 for abdominal pain)
and 2 patients died with symptoms of colon cancer;35 (v) even if
patients develop symptoms related to advanced colorectal cancer,
endoscopic treatment has been increasingly used. One systematic
review demonstrated that self-expanding metallic stents were safe
and effective for relieving malignant colorectal obstruction with a
median clinical success rate of 92%.36 Endoscopic ablative thera-
pies might also be useful in controlling haemorrhagic symptoms;37
(vi) an anastomotic leak after colorectal resection is not uncom-
mon. The rate of an anastomotic leak after a rectal resection in
particular was up to 12%, with a morbidity rate of up to 50%. Such
complications could lead to a delay or even cancellation of both
hepatic surgery and chemotherapy. One study also demonstrated
that up to 50% of patients did not undergo further optimal post-
operative chemotherapy treatment because of post-operative com-
plications after rectal surgery; (vii) metastatic disease rather than
primary colorectal cancer has been proposed to be the main deter-
minant of patient survival and thus treatment of the CLM should
be the first priority.7,17 One systematic review also demonstrated
that downstaging chemotherapy could convert 22.5% of patients
with initially unresectable CLM into ‘resectable’.38 On this basis
many argue that modern chemotherapy should be administered
first and not delayed by the colorectal cancer resection, especially if
surgical complications occur.25 All these findings lend support to
the LFA with upfront modern chemotherapy followed by hepatic
resection in patients with synchronous asymptomatic colorectal
cancer and CLM. This conclusion is further supported by a deci-
sion analysis demonstrating that the optimal management in
patients with colorectal cancer and synchronous resectable CLM
should be upfront systemic chemotherapy.39
Table 4 Surgical characteristics and peri-operative outcomes of bowel resection stage of the liver-first approach (LFA); and survival
outcomes after completion of LFA
Reference Patients
underwent
bowel
resection
n (%)
Bowel Resection Survival Outcomes in patients who completed both hepatic and bowel
resection stages of the LFA
Perioperative
morbidity
n (%)
Perioperative
mortality
n (%)
Number of
patients
completed
both stages
of LFA
Median
Follow-up
(months)
Median OS
(months)
Recurrence
rate
n (%)
3-year
OS (%)
5-year
OS (%)
Mentha16 30/35 (86) 1/30 (3) 0 30 NR 44 20/30 (68%) 60 31
Verhoef17 16/23 (70) NR 0 16 18 19 2/16 (13%) 89 89
Brouquet18 27/41 (66) NR NR 27 25 50 19/27 (70%) 79 39
De Jong19 16/22a (73) 8/16 (50) 1/16 (6) 18b NR 36 6/18 (33%) 41 NR
Total Percentage 89/121 (74) 91/121 (75) 47/91 (52%)
Range 13–70
aExcluding two patients who had a complete response of the rectal cancer after chemoradiation.
bSurvival outcomes included two patients who had a complete response of rectal cancer after chemoradiation and no bowel resection was thus
performed.
OS, overall survival.
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The majority of patients in this review of LFA received up-front
chemotherapy. Although peri-operative chemotherapy (both
before and after liver resection) is associated with improved onco-
logical outcomes, it appears to come at the cost of increased post-
operative morbidity.11 However, given that no high-quality study
compares pre- and post-operative chemotherapy to post-operative
chemotherapy alone, the optimal sequence of liver surgery, colonic
resection and systemic chemotherapy in synchronous CLM is as yet
unresolved. Consideration should be give in particular to liver
damage owing to chemotherapy in the form of steohepatitis (asso-
ciated with irinotecan exposure) and sinusoidal injury (linked to
oxaliplatin administration). This may increase the risk of liver
failure after a resection, particularly if extended in nature. A liver
first approach, prior to systemic treatment, circumvents these issues
and may reduce the risks of post-operative surgical complications.
In the past decade, a simultaneous colorectal cancer resection
and hepatic resection of CLM has been increasingly performed.
Brouquet et al.18 compared the ‘Bowel First’, ‘Simultaneous’ and
‘Liver First’ approaches in the management of 156 consecutive
patients with colorectal cancer and synchronous CLM and found
an equivalent peri-operative morbidity and mortality as well as
survival outcome among all three strategies. One systematic
review comparing simultaneous and staged resection for synchro-
nous CLM also demonstrated the safety and efficacy of the
simultaneous approach in selected patients with comparable
oncological outcomes and fewer overall complications.10 The
major limitation of this review was that all the included studies
were retrospective. In addition, the patients who underwent
simultaneous colorectal and hepatic resection were more likely to
have a right-sided primary tumour, fewer and smaller synchro-
nous CLM and were more likely to require a minor hepatic resec-
tion. Nevertheless, if a simultaneous resection can be performed
without added morbidity and mortality, the potential benefits of
one surgical procedure over two are clear with a shorter total
hospital stay and thus less financial costs.40
In this study, a pooled analysis was conducted where the data
from observational studies were combined as if it were derived
from a single sample. The application of any formal meta-analytic
methods, particularly simple pooling, to observational studies has
been controversial.41 Although combining data by meta-analytic
methods is preferable, it was not feasible in this study.42 It must be
acknowledged that the studies in this review each include a small
number of patients and that there is considerable heterogeneity
evident in their design. Nevertheless, pooling of data provides an
indication of real-world outcomes, but its results must be inter-
preted with caution.
In conclusion, this systematic review demonstrated that LFA is
safe and feasible in selected patients with colorectal cancer and
synchronous CLM and is associated with acceptable peri-
operative and survival outcomes The experience of LFA is in its
infancy and future prospective controlled studies are required to
further define the patient selection criteria for LFA and the exact
role of LFA in the management of synchronous CLM.
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